27632 Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices 

Dated: June 1, 2018. 

Robert W. Patterson, 

Acting Administrator. 

[FR Doc. 2018–12686 Filed 6–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Johnson 

Matthey Pharmaceutical Materials Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before August 13, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on January 

1, 2018, Johnson Matthey 

Pharmaceutical Materials Inc., 25 Patton 

Road, Devens, MA 01434 applied to be 

registered as a bulk manufacturer for the 

basic classes of controlled substances: 

Controlled substance Drug code Schedule 

Amphetamine ................................................................................................................................................................... 1100 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Nabilone ........................................................................................................................................................................... 7379 II 

Hydrocodone ................................................................................................................................................................... 9193 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Alfentanil .......................................................................................................................................................................... 9737 II 

Remifentanil ..................................................................................................................................................................... 9739 II 

Sufentanil ......................................................................................................................................................................... 9740 II 

The company plans to utilize this 

facility to manufacture small quantities 

of the listed controlled substances in 

bulk for distribution to its customers as 

well as to conduct analytical testing in 

support of the company’s primary 

manufacturing facility in West Deptford, 

New Jersey. 

Dated: June 6, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–12685 Filed 6–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Registration 

ACTION: Notice of registration. 

SUMMARY: Registrants listed below have 

applied for and been granted 

registration by-the Drug Enforcement 

Administration (DEA) as importers of 

various classes of schedule I or II 

controlled substances. 

SUPPLEMENTARY INFORMATION: The 

companies listed below applied to be 

registered as importers of various basic 

classes of controlled substances. 

Information on previously published 

notices is listed in the table below. No 

comments or objections were submitted 

and no requests for hearing were 

submitted for these notices. 

Company FR docket Published 

PerkinElmer, Inc ................................................................................................................................................... 83 FR 9337 March 5, 2018. 

Stepan Company .................................................................................................................................................. 83 FR 9337 March 5, 2018. 

Noramco, Inc ........................................................................................................................................................ 83 FR 12408 March 21, 2018. 

Sanyal Biotechnology ........................................................................................................................................... 83 FR 12407 March 21, 2018. 

S&B Pharma, Inc .................................................................................................................................................. 83 FR 13523 March 29, 2018. 

Siegfried USA, LLC .............................................................................................................................................. 83 FR 13521 March 29, 2018. 

Lannett Company, Inc .......................................................................................................................................... 83 FR 13520 March 29, 2018. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823, 952(a) and 

958(a) and determined that the 

registration of the listed registrants to 

import the applicable basic classes of 

schedule I or II controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. The 

DEA investigated each company’s 

maintenance of effective controls 

against diversion by inspecting and 

testing each company’s physical 

security systems, verifying each 

company’s compliance with state and 

local laws, and reviewing each 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 

952(a) and 958(a), and in accordance 

with 21 CFR 1301.34, the DEA has 

granted a registration as an importer for 

schedule I or II controlled substances to 

the above listed companies. 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices 27633 

Dated: May 30, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–12670 Filed 6–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Cambrex Charles City 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before July 13, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 13, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

delegated to the Assistant Administrator 

of the DEA Diversion Control Division 

(‘‘Assistant Administrator’’) pursuant to 

section 7 of 28 CFR part 0, appendix to 

subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on March 

10, 2018, Cambrex Charles City, 1205 

11th Street, Charles City, IA 50616 

applied to be registered as an importer 

of the following basic classes of 

controlled substances: 

Controlled substance Drug code Schedule 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... 8333 II 

Phenylacetone ................................................................................................................................................................. 8501 II 

Coca Leaves .................................................................................................................................................................... 9040 II 

Opium, raw ...................................................................................................................................................................... 9600 II 

Poppy Straw Concentrate ............................................................................................................................................... 9670 II 

The company plans to import the 

listed controlled substances for internal 

use, and to manufacture bulk 

intermediates for sale to its customers. 

Dated: June 6, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–12683 Filed 6–12–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Bellwyck Clinical Services 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before July 13, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 13, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All request for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on April 

4, 2018, Bellwyck Clinical Services, 

8946 Global Way, West Chester, OH 

45069 applied to be registered as an 

importer of the following basic classes 

of controlled substances: 

Controlled substance Drug code Schedule 

Amphetamine ........................................................................................................................................................ 1100 II 

Methylphenidate .................................................................................................................................................... 1724 II 

Oxycodone ............................................................................................................................................................ 9143 II 


amozie on DSK3GDR082PROD with NOTICES1